Nicholas Wealth LLC. Has $2.61 Million Holdings in AbbVie Inc. $ABBV

Nicholas Wealth LLC. increased its position in shares of AbbVie Inc. (NYSE:ABBV) by 20.0% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 14,034 shares of the company’s stock after buying an additional 2,337 shares during the period. AbbVie accounts for 1.3% of Nicholas Wealth LLC.’s holdings, making the stock its 13th biggest holding. Nicholas Wealth LLC.’s holdings in AbbVie were worth $2,605,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. TD Capital Management LLC grew its stake in AbbVie by 82.9% during the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after purchasing an additional 58 shares during the period. Marshall & Sullivan Inc. WA bought a new position in shares of AbbVie during the 2nd quarter worth approximately $25,000. Spurstone Advisory Services LLC acquired a new stake in shares of AbbVie during the 2nd quarter worth approximately $28,000. Financial Gravity Companies Inc. bought a new stake in shares of AbbVie in the 2nd quarter valued at $36,000. Finally, Bear Mountain Capital Inc. lifted its position in shares of AbbVie by 480.6% during the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after acquiring an additional 173 shares during the period. Institutional investors own 70.23% of the company’s stock.

AbbVie Stock Down 0.1%

Shares of NYSE:ABBV opened at $233.83 on Wednesday. The business’s 50 day moving average is $225.84 and its 200 day moving average is $204.57. AbbVie Inc. has a 12-month low of $163.81 and a 12-month high of $244.81. The stock has a market cap of $413.27 billion, a price-to-earnings ratio of 111.35, a PEG ratio of 1.42 and a beta of 0.50. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The firm had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same period in the previous year, the firm earned $3.00 EPS. The business’s revenue for the quarter was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, sell-side analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is currently 524.24%.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on ABBV. Erste Group Bank cut shares of AbbVie from a “buy” rating to a “hold” rating in a research report on Tuesday, October 14th. Citigroup cut their price target on AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a report on Monday, November 3rd. Evercore ISI raised their price objective on AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a research note on Monday, September 22nd. Daiwa Capital Markets upgraded AbbVie from a “neutral” rating to an “outperform” rating and set a $214.00 price objective for the company in a report on Thursday, August 7th. Finally, JPMorgan Chase & Co. increased their target price on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and an average price target of $240.14.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.